Abstract
Ingenol mebutate treatment in actinic keratosis – clinical effectiveness and potential side effects
- Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
- Student Research Group at Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Lodz, Poland
- Department of General and Oncological Surgery, Tomaszow Health Centre, Tomaszow Mazowiecki, Poland
- Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland
Introduction
Actinic keratosis is a common skin disease that occurs in response to prolonged exposure to ultraviolet radiation. This problem affects up to 60% of the population over 40 years of age. Actinic keratosis is considered to be a precancerous lesion leading to squamous cell carcinoma (SCC). The new therapeutic option for the treatment of actinic keratosis is ingenol mebutate gel (0.015%, 0.05%).
Aim
Retrospective evaluation of response and potential side effects of ingenol mebutate treatment in clinical practice.
Material and methods
Eight patients with actinic keratosis lesions on the face or scalp self-applied a 0.015% gel for 3 consecutive days on the 25 cm2 marked area. They were assessed at baseline and on day 4, 7, 14 and 57.
Results
All patients on day 57 presented a complete absence of AK lesions in the area of ingenol mebutate application. No adverse events were observed.
Conclusions
Our study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis.
Keywords
actinic keratosis, ingenol mebutate
Indexed in
Integrated with
